Recent studies have centered on the intersection of GLP|GIP|glucagon receptor agonist therapies and dopaminergic signaling. While GLP agonists are commonly employed for managing type 2 diabetes, their unexpected consequences on motivation circuits, specifically mediated by dopaminergic networks, are receiving significant attention. This report p… Read More